多替阿巴拉米片中国上市了没？

It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. Clinical studies have shown that dolutea abalamide tablets have the characteristics of good tolerability, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life. Today we are going to find out whether Duotai abalami tablets are on the market in China?

On August 27, 2014, Docelotabalamid tablets were approved by the FDA for marketing. Subsequently, on January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation dolutegravir (DTG), a new-generation integrase inhibitor dolutegravir (DTG) as the core, for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Dolutegravir tablets are the only three-in-one compound drug containing dolutegravir. One tablet is taken once a day. It has the characteristics of high efficacy, good tolerability, high resistance barrier and few drug interactions.

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). 

Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP), a deoxyguanosine-5'-triphosphate (dGTP) analogue, under the action of intracellular enzymes. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA. Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity. 

The above is the content of the listing, I hope it can help you!